Diffuse Large B Cell Lymphoma ICD-10-CM Codes | 2023

What ICD-10 Codes are Used for Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL) is a prevalent type of non-Hodgkin lymphoma, and its accurate diagnosis and coding are essential for effective patient care, research, and healthcare management. 

Here, we provide a selection of commonly used DLBCL ICD-10 codes, along with clinical descriptions for each code, helping healthcare professionals precisely categorize this condition:

• C83.30 - Diffuse large B-cell lymphoma, unspecified site: This code is applied when the specific site of DLBCL is not specified, serving as a general code for DLBCL.
• C83.31 - Diffuse large B-cell lymphoma of the lymph nodes: Used when DLBCL primarily affects lymph nodes throughout the body.
• C83.32 - Diffuse large B-cell lymphoma of the spleen: This code is utilized when DLBCL predominantly involves the spleen.
• C83.80 - Other specified types of diffuse large B-cell lymphoma: This code accommodates cases of DLBCL located in rare, non-standard sites not covered by the common categories.
• C83.82 - Diffuse large B-cell lymphoma of the tonsil: Reserved for DLBCL originating in the tonsils.
• C83.83 - Diffuse large B-cell lymphoma of the gastrointestinal tract: This code designates DLBCL found in the gastrointestinal tract, including the stomach and intestines.
• C83.89 - Diffuse large B-cell lymphoma of other specified sites: Used when DLBCL is detected in uncommon locations that lack specific coding.
• C85.10 - Natural killer/T-cell lymphoma, unspecified site: Applied in cases where DLBCL was initially suspected but later diagnosed as a different subtype, like natural killer/T-cell lymphoma.
• D47.02 - Castleman's disease: When Castleman's disease initially mimics DLBCL, this code is assigned upon the correct diagnosis.
• Z85.81 - Personal history of non-Hodgkin lymphomas: This code records the medical history of individuals previously diagnosed with DLBCL, are in remission, or have received treatment.

ICD-10 codes facilitate accurate diagnosis, treatment, and billing in healthcare while also enabling practical data analysis and research on DLBCL. Practitioners and coders must stay updated on these codes to ensure precise documentation and classification of DLBCL cases in clinical and administrative settings.

Which Diffuse Large B Cell Lymphoma ICD Codes are Billable

Let's break down the billability of each commonly used ICD-10 code for Diffuse Large B-Cell Lymphoma (DLBCL):

• C83.30 - Diffuse large B-cell lymphoma, unspecified site: Yes. 
• C83.31 - Diffuse large B-cell lymphoma of the lymph nodes: Yes. 
• C83.32 - Diffuse large B-cell lymphoma of the spleen: Yes. 
• C83.80 - Other specified types of diffuse large B-cell lymphoma: Yes. 
• C83.82 - Diffuse large B-cell lymphoma of the tonsil: Yes. 
• C83.83 - Diffuse large B-cell lymphoma of the gastrointestinal tract: Yes. 
• C83.89 - Diffuse large B-cell lymphoma of other specified sites: Yes. 
• C85.10 - Natural killer/T-cell lymphoma, unspecified site: Yes. 
• D47.02 - Castleman's disease: Yes. 
• Z85.81 - Personal history of non-Hodgkin lymphomas: No, it records the medical history of those previously diagnosed with DLBCL or other non-Hodgkin lymphomas. Billing is associated with active diagnoses and treatments.

Clinical Information

• DLBCL is a type of non-Hodgkin lymphoma characterized by the rapid growth of large B-cells in the lymphatic system.
• It is the most common subtype of non-Hodgkin lymphoma, accounting for approximately 30-40% of cases.
• Patients often present with painless, enlarged lymph nodes, usually in the neck, armpits, or groin.
• B symptoms, such as fever, night sweats, and unexplained weight loss, are common.
• DLBCL can manifest in various subtypes, including primary mediastinal B-cell lymphoma and transformed follicular lymphoma.
• Diagnosis is confirmed through a lymph node biopsy.
• Immunohistochemistry and genetic tests may be performed to determine the specific subtype and guide treatment.
• The Ann Arbor staging system, which ranges from stage I (involving a single lymph node region) to stage IV (widespread disease), is commonly used to assess disease extent.
• Standard treatments include chemoimmunotherapy, typically with regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
• Radiation therapy and stem cell transplantation may be considered in some instances.
• The prognosis varies based on stage, age, and molecular features. Early diagnosis and treatment can lead to a favorable outcome in many cases.
• DLBCL can recur after initial treatment. Salvage chemotherapy and stem cell transplantation are options for relapsed or refractory cases.
• Ongoing research aims to identify novel therapies, molecular markers, and personalized treatment approaches to improve outcomes for DLBCL patients.
• Supportive care, including psychological and social support, is essential for DLBCL patients to cope with the physical and emotional challenges of the disease and its treatment.

Synonyms Include

• Diffuse Large B-Cell Non-Hodgkin Lymphoma
• DLBCL
• Large Cell Lymphoma
• High-Grade B-Cell Lymphoma
• Aggressive B-Cell Lymphoma